As usual, this weeks British Medical Journal is full of great stuff -- it's a theme issue on obesity, and I recommend the commentary by MEJ Lean [yup, that's the good doctor's name. My childhood dentist was Dr. Root.] if you don't have time for the research reports, but what is really jacking up my blood pressure is more on how the FDA works for Merck and Searle and Pfizer, but not for you.
Here's the first two pages of the FDA's review of one of the Cox-2 inhibitors -- you know, those miracle drugs that give you heart attacks?
Credit to some Swiss docs for this, direct link to their article is here. It seems there are certain facts we are not allowed to know about the drugs Searle is selling us because if we did know, it might harm their commercial interests.
Well, that's all I need to know.
Discussion of public health and health care policy, from a public health perspective. The U.S. spends more on medical services than any other country, but we get less for it. Major reasons include lack of universal access, unequal treatment, and underinvestment in public health and social welfare. We will critically examine the economics, politics and sociology of health and illness in the U.S. and the world.
No comments:
Post a Comment
Comments are moderated. You will have to wait for your comment to appear.